Resources

Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has been selected to present at a number of leading international conferences this September.

MyAmici and My Green Lab announce collaboration to support more sustainable lab purchasing. The integration helps life-science labs consider environmental impact alongside price and availability with other purchasing solutions to aid sustainability.

VectorBuilder and Lir Therapeutics formed a strategic collaboration to develop adeno-associated virus (AAV) capsids.

The Milner Therapeutics Institute (MTI) is proud to be part of a new £20 million Medical Research Council (MRC) investment that will establish a UK Pre-clinical Translational Models Hub.

eXmoor Pharma and Evox Therapeutics announce the successful completion of a technology transfer programme for Evox’s exosome-enabled gene editing technology.

The Milner Therapeutics Institute has joined the o2h Discovery Platinum Partner Programme, enabling eligible companies within its bio-incubator and wider affiliate network to access specialist drug discovery support through the o2h Kickstarter Award.

Poolbeg Pharma today announces that the first patient has been dosed in the POLB 001 TOPICAL clinical trial.

Major VectorBee update reflects VectorBuilder’s continued investment in free, researcher-first tools for genetic engineering and vector design.

Autolomous and Cellular Origins today announce end-to-end integration of their respective platforms, bringing full automation and digitisation to the entire cell therapy manufacturing process.

Global drug development consultancy, Boyds has achieved a Bronze Medal from EcoVadis, a global leader in business sustainability assessments.

New technology improves long term efficacy, cost and safety, eliminating trial-and-error in DNA design

Poolbeg Pharma has received formal notification of the decision to grant for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (CRS) patent application.

VectorBuilder announced a strategic partnership with VectorBuilder’s proprietary MiniVec™ plasmid system and MaxCyte’s clinical electroporation platform for ex vivo cell engineering.

Poolbeg Pharma announces new research on two posters, by Poolbeg and The University of Manchester respectively, are being presented at the European Hematology Association Congress.

Poolbeg Pharma, a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the first site activation for the first-in-patient POLB 001 TOPICAL* clinical trial has occurred.

BIA members gathered in London on Tuesday for our 26th annual Parliament Day

Drug Discovery 2026 returns to ExCeL London from 14–15 October to celebrate 20 years of collaboration and inclusion. Keynote programme includes presentation from Dr Sam Barrell CBE and panel discussion with Dr Anne Phelan, Dr Jason Mellad, Prof Sir Mene Pangalos and Prof Raghib Ali OBE

LifeArc partners with Elpida Therapeutics to advance three gene therapies for ultra-rare neurodegenerative diseases in children

Poolbeg announces the positive outcome of a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA)